Blake E Smith
Overview
Explore the profile of Blake E Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu E, Smith B, Conce Alberto W, Walsh M, Lim B, Hoffman M, et al.
bioRxiv
. 2024 Sep;
PMID: 39345591
Tumor-infiltrating-lymphocyte (TIL) therapy has demonstrated that endogenous T cells can be harnessed to initiate an effective anti-tumor response. Despite clinical promise, current TIL production protocols involve weeks-long expansions which can...
2.
Perez C, Garmilla A, Nilsson A, Baghdassarian H, Gordon K, Lima L, et al.
bioRxiv
. 2024 May;
PMID: 38746119
The anti-tumor function of engineered T cells expressing chimeric antigen receptors (CARs) is dependent on signals transduced through intracellular signaling domains (ICDs). Different ICDs are known to drive distinct phenotypes,...
3.
Pandit S, Smith B, Birnbaum M, Brudno Y
Acta Biomater
. 2024 Feb;
177:157-164.
PMID: 38364929
Efficient T cell engineering is central to the success of CAR T cell therapy but involves multiple time-consuming manipulations, including T cell isolation, activation, and transduction. These steps add complexity...
4.
Smith B, Chan A, Birnbaum M
Cell Rep Methods
. 2024 Jan;
4(1):100694.
PMID: 38262348
In a recent issue of Cell, Dezfulian et al. develop a genome-scale platform to enable high-throughput identification of CD4 T cell epitopes. This platform enables unbiased screens to discover antigens...
5.
Dobson C, Reich A, Gaglione S, Smith B, Kim E, Dong J, et al.
Nat Methods
. 2022 Apr;
19(4):449-460.
PMID: 35396484
Deciphering immune recognition is critical for understanding a broad range of diseases and for the development of effective vaccines and immunotherapies. Efforts to do so are limited by a lack...
6.
Bondeson D, Smith B, Buhimschi A
Methods Mol Biol
. 2021 Aug;
2365:135-150.
PMID: 34432242
Assessing the specificity of PROTACs and confirming their proposed mechanism of action are critical for a robust targeted protein degradation program. Owing to their novel mechanism, new assays are needed...
7.
Smith B, Wang S, Jaime-Figueroa S, Harbin A, Wang J, Hamman B, et al.
Nat Commun
. 2019 Jan;
10(1):131.
PMID: 30631068
PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation. Many potent PROTACs with specificity for dissimilar targets...
8.
Bondeson D, Smith B, Burslem G, Buhimschi A, Hines J, Jaime-Figueroa S, et al.
Cell Chem Biol
. 2017 Nov;
25(1):78-87.e5.
PMID: 29129718
Inhibiting protein function selectively is a major goal of modern drug discovery. Here, we report a previously understudied benefit of small molecule proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases...
9.
Burslem G, Smith B, Lai A, Jaime-Figueroa S, McQuaid D, Bondeson D, et al.
Cell Chem Biol
. 2017 Nov;
25(1):67-77.e3.
PMID: 29129716
Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the development of PROTACs for...